Aliliin monoclonal antibody as well as preparation method and application thereof

CN118894941AActive Publication Date: 2024-11-05XINJIANG MEDICAL UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411269641.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-11
Publication Date
2024-11-05
Estimated Expiration
2044-09-11

AI Technical Summary

Technical Problem

The difficulty in developing alliin monoclonal antibodies is that alliin, as a small molecule substance, lacks immunogenicity and cannot directly stimulate the body to produce antibodies. It needs to be coupled with the carrier protein to form a complete antigen.

Method used

By coupling alliin to hemocyanin (KLH), a complete immunogenic antigen was formed, and specific preferred antibodies 1A10, 1F3 and 3E12 were screened out, and these antibodies were expressed and purified by recombinant technology for detection of samples. The presence of alliin.

Benefits of technology

A monoclonal antibody with high titer and high affinity was obtained, which can effectively detect alliin in the body. It is suitable for the detection of garlic and its related products, and has high immunogenicity and stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005038322060000071
    Figure BDA0005038322060000071
  • Figure BDA0005038322060000081
    Figure BDA0005038322060000081
  • Figure BDA0005038322060000111
    Figure BDA0005038322060000111
Patent Text Reader

Abstract

The invention provides an alliin monoclonal antibody as well as a preparation method and application thereof. Specifically, the invention provides an anti-alliin antibody or an antigen binding fragment thereof, and the anti-alliin antibody or the antigen binding fragment thereof has very excellent specificity and can be used for effectively detecting alliin in a sample to be detected.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biological preparations, and in particular, relates to an alliin monoclonal antibody and a preparation method and application thereof. Background Art

[0002] Alliin is a sulfur-containing amino acid characteristic of garlic, containing carboxyl and amino groups, with a molecular formula of C6H 11 NO3S, with a relative molecular mass of 177.22, is stable in nature. Domestic and foreign studies have shown that alliin has antibacterial, non-alcoholic fatty liver disease improvement, myocardial protection and immune regulation effects.

[0003] Immunoassay is based on antigen-antibody specific reaction to achieve the purpose of rapid detection of small molecules. The preparation of antibodies is a hot topic and difficulty in research. Since alliin is a small molecule and has no immunogenicity, it needs to be coupled with a carrier protein to form a complete antigen. Whether the conjugate is immunogenic and stimulates the body to produce antibodies is the key to the preparation of alliin antibodies.

[0004] Therefore, developing an antibody against a complete antigen including the hapten alliin for use in garlic, garlic-related medicines, health foods and health products (disinfection products, foods), and the effective detection of alliin in biological samples (blood, tissue samples) in the body after taking the above products is of great value to the basic research on garlic and the clinical research on garlic preparations. Summary of the invention

[0005] The invention provides an alliin monoclonal antibody and a preparation method and application thereof.

[0006] In the first aspect of the present invention, an anti-alliin antibody or an antigen-binding fragment thereof is provided, wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the complementarity determining region CDR (HCDR) of the heavy chain variable region and the complementarity determining region CDR (LCDR) of the light chain variable region are selected from the following group:

[0007] (1) HCDR1 with an amino acid sequence as shown in SEQ ID NO: 3,

[0008] The amino acid sequence of HCDR2 is shown in SEQ ID NO:4,

[0009] The amino acid sequence of HCDR3 is shown in SEQ ID NO:5,

[0010] LCDR1 having an amino acid sequence as shown in SEQ ID NO: 10,

[0011] LCDR2 having an amino acid sequence as shown in SEQ ID NO: 11, and

[0012] LCDR3 having an amino acid sequence as shown in SEQ ID NO:12;

[0013] (2) HCDR1 with an amino acid sequence as shown in SEQ ID NO: 17,

[0014] The amino acid sequence of HCDR2 is shown in SEQ ID NO: 18,

[0015] The amino acid sequence of HCDR3 is shown in SEQ ID NO: 19,

[0016] LCDR1 having an amino acid sequence as shown in SEQ ID NO: 24,

[0017] LCDR2 having an amino acid sequence as shown in SEQ ID NO: 25, and

[0018] LCDR3 having an amino acid sequence as shown in SEQ ID NO:12;

[0019] (3) HCDR1 with an amino acid sequence as shown in SEQ ID NO: 30,

[0020] The amino acid sequence of HCDR2 is shown in SEQ ID NO: 18,

[0021] The amino acid sequence of HCDR3 is shown in SEQ ID NO:31,

[0022] LCDR1 having an amino acid sequence as shown in SEQ ID NO:36,

[0023] LCDR2 having an amino acid sequence as shown in SEQ ID NO: 11, and

[0024] The amino acid sequence of LCDR3 is shown in SEQ ID NO:37.

[0025] In another preferred embodiment, the heavy chain variable region and light chain variable region of the antibody or antigen-binding fragment thereof are selected from the following groups:

[0026] (1) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO: 1, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 8;

[0027] (2) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO: 15, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 22;

[0028] (3) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:28, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:34.

[0029] In another preferred example, the heavy chain variable region includes the three complementary determining regions HCDR and a framework region of the heavy chain variable region used to connect the heavy chain variable region HCDR; the light chain variable region includes the three light chain complementary determining regions LCDR and a framework region of the light chain variable region used to connect the light chain complementary determining regions LCDR.

[0030] In another preferred embodiment, the anti-alliin antibody or antigen-binding fragment thereof is selected from the following group: Fab fragment, Fab' fragment, F(ab)'2 fragment, F(ab)'3 fragment, Fv, single-chain Fv antibody ("scFv"), double scFv, (scFv)2.

[0031] In another preferred example, the light chain of the antibody further includes a light chain constant region.

[0032] In another preferred embodiment, the light chain constant region is of rabbit origin.

[0033] In another preferred embodiment, the heavy chain of the antibody further includes a heavy chain constant region.

[0034] In another preferred embodiment, the heavy chain constant region is of rabbit origin.

[0035] In another preferred embodiment, the antibody is a double-chain antibody or a single-chain antibody.

[0036] In another preferred embodiment, the antibody is a monoclonal antibody.

[0037] In another preferred embodiment, the antibody includes a monospecific, bispecific, trispecific antibody or a multispecific antibody.

[0038] In a second aspect of the present invention, a recombinant protein is provided, wherein the recombinant protein has:

[0039] (i) the anti-alliin antibody or antigen-binding fragment thereof according to the first aspect of the present invention;

[0040] and (ii) optionally a tag sequence to facilitate expression and / or purification.

[0041] In another preferred embodiment, the tag sequence includes a 6His tag.

[0042] In another preferred embodiment, the recombinant protein (or polypeptide) includes a fusion protein.

[0043] In another preferred embodiment, the recombinant protein is a monomer, a dimer, or a polymer.

[0044] In the third aspect of the present invention, a nucleotide molecule is provided, wherein the nucleotide molecule encodes the anti-alliin antibody or antigen-binding fragment thereof according to the first aspect of the present invention.

[0045] In another preferred example, the nucleotide molecule comprises a nucleotide sequence encoding a heavy chain variable region as shown in SEQ ID NO: 2, and a nucleotide sequence encoding a light chain variable region as shown in SEQ ID NO: 9.

[0046] In another preferred example, the nucleotide molecule comprises a nucleotide sequence encoding a heavy chain variable region as shown in SEQ ID NO: 16, and a nucleotide sequence encoding a light chain variable region as shown in SEQ ID NO: 23.

[0047] In another preferred example, the nucleotide molecule comprises a nucleotide sequence encoding a heavy chain variable region as shown in SEQ ID NO: 29, and a nucleotide sequence encoding a light chain variable region as shown in SEQ ID NO: 35.

[0048] In the fourth aspect of the present invention, a vector is provided, wherein the vector contains the nucleotide molecule described in the first aspect of the present invention.

[0049] In the fifth aspect of the present invention, a host cell is provided, wherein the host cell contains the vector described in the fourth aspect of the present invention, or has the nucleotide molecule described in the third aspect of the present invention integrated into its genome, or expresses the anti-alliin antibody or antigen-binding fragment thereof described in the first aspect of the present invention.

[0050] In a sixth aspect of the present invention, a method for detecting alliin in a sample is provided, the method comprising the steps of:

[0051] (1) contacting a sample with the anti-alliin antibody or antigen-binding fragment thereof according to the first aspect of the present invention;

[0052] (2) Detecting whether a hapten-antibody complex is formed, wherein the formation of the complex indicates the presence of alliin in the sample.

[0053] In a seventh aspect of the present invention, there is provided a method for preparing the anti-alliin antibody or antigen-binding fragment thereof according to the first aspect of the present invention, the method comprising the following steps:

[0054] (a) culturing the host cell according to the fifth aspect of the present invention under expression conditions, thereby expressing the anti-alliin antibody or antigen-binding fragment thereof;

[0055] (b) isolating and purifying the anti-alliin antibody or antigen-binding fragment thereof described in (a).

[0056] In the eighth aspect of the present invention, there is provided a use of the anti-alliin antibody or antigen-binding fragment thereof described in the first aspect of the present invention and the recombinant protein described in the second aspect of the present invention for preparing a reagent, a detection plate or a kit;

[0057] The reagent, detection plate or test kit is used for detecting whether a sample contains alliin, or for capturing alliin.

[0058] In the ninth aspect of the present invention, a detection plate is provided, which includes a substrate (support sheet) and a test strip, wherein the test strip contains the anti-alliin antibody or its antigen-binding fragment as described in the first aspect of the present invention, or the recombinant protein as described in the second aspect of the present invention.

[0059] In another preferred embodiment, the test strip further comprises an antigen spotting area.

[0060] In another preferred embodiment, the antigen is a hapten or a complete antigen.

[0061] In another preferred embodiment, the test strip is composed of filter paper, chromatography material, nitrocellulose membrane and absorbent paper overlapped in sequence.

[0062] In the tenth aspect of the present invention, a kit is provided, which comprises a container and the anti-alliin antibody or antigen-binding fragment thereof according to the first aspect of the present invention located in the container, or the kit comprises the detection plate and instructions for use according to the ninth aspect of the present invention.

[0063] In another aspect of the present invention, a kit is provided, comprising:

[0064] (1) a first container, wherein the first container contains the anti-alliin antibody or antigen-binding fragment thereof according to the first aspect of the present invention; and / or

[0065] (2) a second container, wherein the second container contains a second antibody, wherein the second antibody is directed against the anti-alliin antibody or antigen-binding fragment thereof according to the first aspect of the present invention; and / or

[0066] (3) a third container, wherein the third container contains a cell lysis reagent;

[0067] or,

[0068] The kit contains the detection plate as described in the ninth aspect of the present invention.

[0069] In another preferred embodiment, the antibody in the first container is detectably labeled.

[0070] In another preferred embodiment, the antibody in the second container is detectably labeled.

[0071] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0072] Figure 1 AC respectively show the expression and purification test results of 1A10, 1F3 and 3E12 cloned recombinant antibodies (Coomassie Brilliant Blue staining): M: protein marker, IN: original sample, FT: flow-through, W: washing solution, E: eluate.

[0073] Figure 2 The titer curve of the antibody 1A10 of the present invention is shown.

[0074] Figure 3 The titer curve of the antibody 1F3 of the present invention is shown.

[0075] Figure 4 The titer curve of the antibody 3E12 of the present invention is shown. DETAILED DESCRIPTION

[0076] After extensive and in-depth research, the inventors have developed a complete antigen based on alliin hapten and hemocyanin (KLH) for the first time, and through a large number of screenings, developed and obtained specific preferred antibodies (1A10, 1F3 and 3E12) based on the antigen. The antiserum titer of the antibody of the present invention can reach 1:32K, and the antibody of the present invention has good affinity. The antibody of the present invention can be used for garlic, garlic-related medicines, health foods and health products (disinfection products, foods), and effective detection of alliin in biological samples (blood, tissue samples) in vivo after taking the above products. The present invention was completed on this basis.

[0077] the term

[0078] In order to more easily understand the present invention, some technical and scientific terms are specifically defined below. Unless otherwise clearly defined in this article, all other technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art to which the present invention belongs. Before describing the present invention, it should be understood that the present invention is not limited to the specific methods and experimental conditions described, because such methods and conditions can be changed. It should also be understood that the terms used herein are intended only to describe specific embodiments, and are not intended to be restrictive, and the scope of the present invention will be limited only by the appended claims.

[0079] As used herein, when used in reference to a specific recited numerical value, the term "about" means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes all values ​​between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0080] As used herein, the terms "comprise", "include", and "contain" are used interchangeably and include not only closed definitions, but also semi-closed and open definitions. In other words, the terms include "consisting of", "consisting essentially of".

[0081] Hapten

[0082] Alliin is a sulfur-containing amino acid characteristic of garlic, containing carboxyl and amino groups, with a molecular formula of C6H 11 NO3S, with a relative molecular mass of 177.22, is stable in nature. Domestic and foreign studies have shown that alliin has antibacterial, non-alcoholic fatty liver disease improvement, myocardial protection and immune regulation effects.

[0083] Alliin has a very small molecular weight and is a hapten substance. It only has immunoreactivity but no immunogenicity and cannot be directly used to immunize animals to obtain antibodies. Therefore, the present invention uses alliin to couple with a carrier protein KLH (hemocyanin) to form an immunogenic complex, thereby inducing an immune response and producing corresponding antibodies.

[0084] As used herein, the "hapten" of the present invention refers to alliin.

[0085] Complete antigen

[0086] Usually, a hapten needs to be covalently coupled to a macromolecule such as KLH (hemocyanin) or BSA (bovine serum albumin) to become a complete antigen that is both immunoreactive and immunogenic.

[0087] As used herein, the "complete antigen" of the present invention refers to the product of combining the hapten of the present invention with an appropriate protein carrier.

[0088] As used herein, the "protein carrier" in the present invention refers to any immunologically acceptable protein used to form a complete antigen, which may be, for example, hemocyanin, bovine serum albumin, and the like.

[0089] The complete antigen prepared by the present invention, alliin-KLH, has good immunogenicity and can stimulate New Zealand white rabbits to produce a strong immune response. After one basic immunization and three booster immunizations, the antiserum titer can reach 1:32K; the complete antigen alliin-KLH well retains the immunoreactivity of alliin.

[0090] Antibody

[0091] In the present invention, the terms "antibody (Ab)" and "immunoglobulin G (IgG)" are heterotetrameric glycoproteins with the same structural characteristics, which are composed of two identical light chains (L) and two identical heavy chains (H). Each light chain is connected to the heavy chain by a covalent disulfide bond, and the number of disulfide bonds between heavy chains of different immunoglobulin isotypes is different. Each heavy chain and light chain also has regularly spaced intrachain disulfide bonds. One end of each heavy chain has a variable region (VH), followed by a constant region, and the heavy chain constant region is composed of three domains CH1, CH2, and CH3. One end of each light chain has a variable region (VL) and the other end has a constant region, and the light chain constant region includes a domain CL; the constant region of the light chain is paired with the CH1 domain of the heavy chain constant region, and the variable region of the light chain is paired with the variable region of the heavy chain. The constant regions are not directly involved in the binding of antibodies to antigens, but they exhibit different effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC). The heavy chain constant region includes IgG1, IgG2, IgG3, and IgG4 subtypes; the light chain constant region includes κ (Kappa) or λ (Lambda). The heavy chain and light chain of the antibody are covalently linked together by disulfide bonds between the CH1 domain of the heavy chain and the CL domain of the light chain, and the two heavy chains of the antibody are covalently linked together by inter-polypeptide disulfide bonds formed between the hinge regions.

[0092] In the present invention, the terms "Fab" and "Fc" refer to the fact that papain can cleave antibodies into two identical Fab segments and one Fc segment. The Fab segment is composed of the VH and CH1 domains of the heavy chain and the VL and CL domains of the light chain of the antibody. The Fc segment is the crystallizable fragment (Fc), which is composed of the CH2 and CH3 domains of the antibody. The Fc segment has no antigen binding activity and is the site where the antibody interacts with effector molecules or cells.

[0093] In the present invention, the term "scFv" refers to a single chain antibody fragment (scFv), which is composed of an antibody heavy chain variable region and a light chain variable region connected by a linker of usually 15 to 25 amino acids.

[0094] In the present invention, the term "variable" means that some parts of the variable region in the antibody are different in sequence, which form the binding and specificity of various specific antibodies to their specific antigens. However, variability is not evenly distributed throughout the variable region of the antibody. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions in the heavy chain variable region and the light chain variable region. The more conservative part of the variable region is called the framework region (FR). The variable region of the natural heavy chain and light chain each contains four FR regions, which are roughly in a β-folded configuration, connected by three CDRs forming a connecting loop, and in some cases can form a partial β-folded structure. The CDRs in each chain are closely together through the FR region and together with the CDRs of the other chain form the antigen binding site of the antibody (see Kabat et al., NIH Publ. No. 91-3242, Volume I, pp. 647-669 (1991)).

[0095] As used herein, the term "framework region" (FR) refers to the amino acid sequence inserted between CDRs, i.e., refers to those parts of the light chain and heavy chain variable regions of immunoglobulins that are relatively conserved between different immunoglobulins in a single species. The light chain and heavy chain of immunoglobulins each have four FRs, respectively referred to as L-FR1, L-FR2, L-FR3, L-FR4 and H-FR1, H-FR2, H-FR3, H-FR4. Accordingly, the light chain variable domain can therefore be referred to as:

[0096] (L-FR1)-(L-CDR1)-(L-FR2)-(L-CDR2)-(L-FR3)-(L-CDR3)-(L-FR4) and the heavy chain variable domain can therefore be expressed as (H-FR1)-(H-CDR1)-(H-FR2)-(H-CDR2)-(H-FR3)-(H-CDR3)-(H-FR4). Preferably, the FR of the present invention is a human antibody FR or a derivative thereof, and the derivative of the human antibody FR is substantially identical to the naturally occurring human antibody FR, i.e., the sequence identity reaches 85%, 90%, 95%, 96%, 97%, 98% or 99%.

[0097] Knowing the amino acid sequences of the CDRs, one skilled in the art can easily determine the framework regions L-FR1, L-FR2, L-FR3, L-FR4 and / or H-FR1, H-FR2, H-FR3, H-FR4.

[0098] As used herein, the term "human framework region" is a framework region that is substantially identical (about 85% or more, specifically 90%, 95%, 97%, 99% or 100%) to the framework region of a naturally occurring human antibody.

[0099] As used herein, the term "linker" refers to one or more amino acid residues inserted into an immunoglobulin domain that provide sufficient mobility for the domains of the light chain and the heavy chain to fold into an exchange dual variable region immunoglobulin. In the present invention, preferred linkers refer to linkers Linker1 and Linker2, wherein Linker1 connects the VH and VL of a single-chain antibody (scFv), and Linker2 is used to connect scFv to the heavy chain of another antibody.

[0100] Examples of suitable linkers include single glycine (Gly), or serine (Ser) residues. The identity and sequence of the amino acid residues in the linker may vary depending on the type of secondary structural element that is desired to be achieved in the linker.

[0101] In the present invention, the antibody of the present invention also includes conservative variants thereof, which refers to polypeptides formed by replacing at most 10, preferably at most 8, more preferably at most 5, and most preferably at most 3 amino acids with amino acids having similar or similar properties compared to the amino acid sequence of the bispecific antibody of the present invention. These conservative variant polypeptides are preferably generated by amino acid substitution according to Table A.

[0102] Table A

[0103]

[0104]

[0105] In the present invention, the terms "anti", "binding", "specific binding" refer to a non-random binding reaction between two molecules, such as the reaction between an antibody and an antigen to which it is directed. Typically, an antibody binds to the antigen with an equilibrium dissociation constant (KD) less than about 10-7M, for example, less than about 10-8M, 10-9M, 10-10M, 10-11M or less. In the present invention, the term "KD" refers to the equilibrium dissociation constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding, and the higher the affinity between the antibody and the antigen. For example, the binding affinity of an antibody to an antigen is measured in a BIACORE instrument using surface plasmon resonance (SPR) or the relative affinity of an antibody to an antigen is measured using ELISA.

[0106] In the present invention, the term "epitope" refers to a polypeptide determinant that specifically binds to an antibody. The epitope of the present invention is a region of an antigen that is bound by an antibody.

[0107] The present invention also provides a polynucleotide molecule encoding the above-mentioned antibody or its fragment or its fusion protein. The polynucleotide of the present invention can be in the form of DNA or RNA. The DNA form includes cDNA, genomic DNA or artificially synthesized DNA. The DNA can be single-stranded or double-stranded. The DNA can be a coding strand or a non-coding strand.

[0108] Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant methods. This is usually done by cloning it into a vector, then transferring it into cells, and then isolating the relevant sequence from the propagated host cells by conventional methods.

[0109] The present invention also relates to vectors comprising the above-mentioned appropriate DNA sequence and appropriate promoter or control sequence. These vectors can be used to transform appropriate host cells to enable them to express proteins.

[0110] Antibody preparation

[0111] The sequence of the DNA molecule of the antibody of the present invention or its fragment can be obtained by conventional techniques, such as PCR amplification or genomic library screening. In addition, the coding sequences of the light chain and the heavy chain can be fused together to form a single-chain antibody.

[0112] Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant methods. This is usually done by cloning it into a vector, then transferring it into cells, and then isolating the relevant sequence from the propagated host cells by conventional methods.

[0113] In addition, artificial synthesis methods can also be used to synthesize related sequences, especially when the fragment length is shorter. Usually, a long fragment of sequence can be obtained by synthesizing multiple small fragments first and then connecting them.

[0114] At present, the DNA sequence encoding the antibody (or its fragment, or its derivative) of the present invention can be obtained completely by chemical synthesis. The DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art. In addition, mutations can also be introduced into the protein sequence of the present invention by chemical synthesis.

[0115] The present invention also relates to vectors comprising the above-mentioned appropriate DNA sequence and appropriate promoter or control sequence. These vectors can be used to transform appropriate host cells to enable them to express proteins.

[0116] The host cell can be a prokaryotic cell, such as a bacterial cell, a lower eukaryotic cell, such as a yeast cell, or a higher eukaryotic cell, such as a mammalian cell. Preferred animal cells include (but are not limited to): CHO-S, HEK-293 cells.

[0117] Typically, the transformed host cells are cultured under conditions suitable for the expression of the antibodies of the present invention, and then purified using conventional immunoglobulin purification steps, such as protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, ion exchange chromatography, hydrophobic chromatography, molecular sieve chromatography or affinity chromatography, etc., conventional separation and purification means well known to those skilled in the art to obtain the antibodies of the present invention.

[0118] The resulting monoclonal antibodies can be identified by conventional means. For example, the binding specificity of the monoclonal antibodies can be determined by immunoprecipitation or in vitro binding assays such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA). The binding affinity of the monoclonal antibodies can be determined, for example, by the Scatchard analysis of Munson et al., Anal. Biochem., 107:220 (1980).

[0119] The antibodies of the present invention can be expressed in cells, on cell membranes, or secreted outside cells. If necessary, the recombinant protein can be separated and purified by various separation methods using its physical, chemical and other properties. These methods are well known to those skilled in the art. Examples of these methods include but are not limited to: conventional renaturation treatment, treatment with protein precipitants (salting out method), centrifugation, osmotic sterilization, ultrasonic treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography techniques and combinations of these methods.

[0120] Test Uses and Kits

[0121] The antibodies of the present invention can be used in detection applications, such as for detecting samples, thereby providing detection information.

[0122] In the present invention, the samples (specimens) used include garlic, garlic-related medicines, health foods and health products (disinfection products, foods), cells, and tissue samples.

[0123] The samples used in the present invention include fixed or preserved garlic, garlic-related medicines, health foods and health products (disinfectant products, foods), cells or tissue samples.

[0124] The present invention also provides a kit containing the antibody (or fragment thereof) of the present invention. In a preferred embodiment of the present invention, the kit further comprises a container, instructions for use, a buffer, etc. In a preferred embodiment, the antibody of the present invention can be fixed to a detection plate.

[0125] The main advantages of the present invention include:

[0126] (a) The complete antigen of the present invention has high immunogenicity and retains the immunoreactivity of alliin.

[0127] (b) The anti-alliin monoclonal antibodies 1A10, 1F3 and 3E12 of the present invention have excellent specificity and high titer, reaching 1:32K.

[0128] (c) In the animal immunization of the present invention, New Zealand white rabbits are selected as experimental animals. Rabbit monoclonal antibodies have the advantages of high specificity, high diversity, high stability and high affinity.

[0129] (d) The anti-alliin monoclonal antibodies 1A10, 1F3 and 3E12 of the present invention have good affinity.

[0130] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.

[0131] Example 1 Preparation of Alliin-KLH Complete Antigen

[0132] The antigen preparation method of the present invention is as follows: the immune antigen is prepared by coupling the natural alliin small molecule hapten with the carrier protein KLH (hemocyanin). Specifically, it includes the following steps:

[0133] (1) 1 mg of protein was dialyzed / dissolved into 1 ml of 25 mM 2-(N-morpholino) (MES) ethanesulfonic acid, and 1 mg of alliin was added and mixed to dissolve;

[0134] (2) adding 0.5 ml of 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) solution to 1 ml of antigen-alliin small molecule mixture;

[0135] (3) Add 0.16 ml of 25 mM MES (pH = 5) to the mixture in (2);

[0136] (4) Mix and incubate at 4°C for 2 h;

[0137] (5) Dialyze three times at 4°C, 2 h each time, to remove the unbound alliin small molecules in a free state.

[0138] Example 2 Preparation of alliin monoclonal antibody

[0139] 2.1 Animal immunization

[0140] Eight (A, B, C, D, E, F, G, H) healthy female New Zealand white rabbits aged 4 months, weighing 2.1 kg, were selected. The specific immunization procedure is shown in Table 1.

[0141] Table 1 Immunization schedule

[0142]

[0143] Final release: whole blood was collected from the carotid artery, and serum was collected and cryopreserved after standing at 4°C overnight. Spleen cells were collected and cryopreserved in liquid nitrogen.

[0144] After the second and fourth immunizations, the serum titer was tested by indirect ELISA. The specific steps are as follows:

[0145] (1) Coating antigen: Dilute the BSA-alliin screening agent to 2 μg / ml with 0.05 mol / L carbonate (pH=9.6), 100 μl / well, and incubate overnight at 4°C. Pour off the solution in the plate and wash three times with 0.05% Tween-20 (PBST), each wash for 3 minutes.

[0146] (2) Blocking: Add 150 μl of 5% skimmed milk powder to each well and block at 37°C for 60 min.

[0147] (3) Washing the plate: Wash the plate three times with PBST, 3 min each time.

[0148] (4) Add primary antibody: dilute the antiserum starting from 1:1000 and incubate at 37°C for 1 h. Pour off the solution in the plate and wash three times with PBST, 3 min each time.

[0149] (5) Add secondary antibody: horseradish enzyme-labeled goat anti-rabbit IgG (H+L), dilute 1:5000, incubate at 37°C for 45 minutes. Pour off the solution in the plate and wash five times with 0.05% Tween-20 (PBST), 3 minutes each time.

[0150] (6) Color development: Add TMB color development solution (100 μl / well), react for 10 minutes, and add 100 μl 2 mol / L sulfuric acid to terminate the reaction.

[0151] (7) Determination: OD value was measured at 450 nm using an enzyme-labeled instrument.

[0152] The results of the indirect ELISA test on the serum after the second immunization are shown in Table 2. The results of the indirect ELISA test on the serum after the fourth immunization are shown in Table 3.

[0153] Table 2 Results of indirect ELISA test on serum after the second immunization

[0154]

[0155]

[0156] Table 3 Results of indirect ELISA test on serum after four immunizations

[0157] A Rabbit B Rabbit C Rabbit D Rabbit E Rabbit F Rabbit G Rabbit H Rabbit Blank control 0.045 0.055 0.051 0.062 0.047 0.052 0.059 0.051 2K 2.296 0.924 2.151 2.231 1.833 2.26 1.759 1.156 4K 1.984 0.594 1.967 1.908 1.686 2.011 1.407 0.686 8K 1.879 0.344 1.682 1.694 1.194 1.846 1.084 0.502 16K 1.679 0.206 1.407 1.385 0.835 1.476 0.819 0.341 32K 1.209 0.158 1.023 1.103 0.572 1.079 0.502 0.298 64K 0.999 0.140 0.554 0.591 0.386 0.954 0.324 0.151 128K 0.629 0.134 0.389 0.344 0.288 0.620 0.285 0.144

[0158] In Table 2 and Table 3, the higher the OD value, the stronger the antiserum titer. Finally, the antisera of rabbit A, rabbit C, rabbit D and rabbit F were selected for competitive ELISA detection. The specific steps of competitive ELISA detection are as follows:

[0159] (1) Coating antigen: Dilute the BSA-alliin screening agent to 2 μg / ml with 0.05 mol / L carbonate (pH=9.6), 100 μl / well, and incubate overnight at 4°C. Pour off the solution in the plate and wash three times with 0.05% Tween-20 (PBST), each wash for 3 minutes.

[0160] (2) Blocking: Add 150 μl of 5% skimmed milk powder to each well and block at 37°C for 60 min.

[0161] (3) Washing the plate: Wash the plate three times with PBST, 3 minutes each time.

[0162] (4) Adding primary antibody: dilute the antiserum at 1:32000, mix with 100 μg / well competitor alliin molecule (diluted in 2-fold gradient), and incubate at 37°C for 1 h. Pour off the solution in the plate and wash three times with PBST, 3 min each time.

[0163] (5) Add secondary antibody: horseradish enzyme-labeled goat anti-rabbit IgG (H+L), dilute 1:5000, incubate at 37°C for 45 min. Pour off the solution in the plate and wash five times with PBST, 3 min each time.

[0164] (6) Color development: Add TMB color development solution (100 μl / well), react for 10 min, and add 100 μl 2 mol / L sulfuric acid to terminate the reaction.

[0165] (7) Determination: OD value was measured at 450 nm using an enzyme-labeled instrument.

[0166] The results of the serum competition ELISA test after four immunizations are shown in Table 4.

[0167] Table 4 Results of ELISA test on serum competition after four immunizations

[0168]

[0169]

[0170] 2.2B Cell Collection

[0171] Peripheral blood B cells were collected, and the cells were washed twice with 1×PBS buffer, with a volume of 50 ml / time, and centrifuged at 1500 rpm / min for 5 min. The supernatant was discarded and the B cells were collected.

[0172] 2.3 Single B cell screening

[0173] Positive B cells were screened by flow cytometry and antigen specificity.

[0174] 2.4 Cloning

[0175] After screening, the positive B cells were counted and then limitedly diluted, plated in a 96-well plate, and cultured with M40105 medium. After 15 days of culture, the supernatant was taken for indirect ELISA, and 65 clones with high positive values ​​(OD values) were selected for subsequent competitive ELISA detection. The four groups with the highest difference between the competition group and the control group were selected for subsequent experiments, and finally four clones, 1A10, 1F3, 2F3 and 3E12, were selected.

[0176] Among them, the results of indirect ELISA detection of B cell culture supernatant are shown in Table 5, and the results of competitive ELISA detection of B cell culture supernatant are shown in Table 6.

[0177] Table 5B Indirect ELISA test results of cell culture supernatant

[0178]

[0179]

[0180] Note: The bold black parts in the table are candidate positive clones.

[0181] Table 6B Cell culture supernatant competition ELISA test results

[0182]

[0183]

[0184] Note: The bold black part in the table is the candidate competitive positive clone; the primary antibody of the control group is 50μl PBS + 50μl 96-well positive supernatant screened in the first round; the primary antibody of the competition group is 50μl (concentration 20μg / ml, i.e. 1μg per well) alliin and 50μl 96-well positive supernatant screened in the first round.

[0185] 2.5 Single B cell sequencing

[0186] RNA was extracted from single B cells of four clones, 1A10, 1F3, 2F3 and 3E12, and then reverse transcribed and amplified to obtain heavy and light chain sequences, which were then sequenced. The sequencing results of antibodies 1A10, 1F3 and 3E12 are shown in Table B of the present invention.

[0187] Example 3 Expression of recombinant alliin antibody

[0188] 3.1 Expression and purification test

[0189] Based on the sequencing results in Example 2, the target genes (VH and VL coding sequences) of four monoclonal antibodies were transfected (transiently transfected) into HEK293 cells (human embryonic kidney 239 cells) for protein expression and purification tests.

[0190] The specific transfection experimental process is as follows:

[0191] (1) According to 0.5×10 6 Inoculate cells into 300 ml of culture medium in a 1 L shake flask.

[0192] (2) Incubate in a shaking incubator at 37°C, 120 rpm, and 5% carbon dioxide for 24 h until the cell density reaches 1×10 6 cells / ml.

[0193] (3) Pipette 300 μg of DNA (sterilized by filtration) and add it to 30 ml of PBS. Then vortex for 3 seconds to mix thoroughly.

[0194] (4) Add 1.2 ml of filter-sterilized Lip2000 solution to the PBS / DNA mixture.

[0195] (5) The Lip2000-DNA mixture was allowed to stand at room temperature for 20 min.

[0196] (6) Add the DNA / Lip2000 mixture to the cells. The cell density must reach 1.5-2.0×10 6 cells / ml.

[0197] (7) After transfection, the cells were cultured in a shaking incubator at 37°C, 120 rpm, and 5% carbon dioxide concentration for 6 days.

[0198] (8) Centrifuge at 3000 × g for 5 min to collect the culture supernatant and cell pellet and store at -80°C or use for subsequent purification.

[0199] 3.2 Expression conditions

[0200] HEK293 cell density: 1.5-2.0×10 6 cells / ml; culture temperature: 37℃; culture speed: 130rmp / min; culture sampling time: Day6.

[0201] 3.3 Purification scheme

[0202] The specific steps are as follows:

[0203] (1) The resin was washed three times with 100 mM potassium acetate and 50 mM Tris (pH 7.5), and then equilibrated with PBS (pH 7.4).

[0204] (2) Use 1.25 ml of ProA column material per liter of culture. Incubate the culture supernatant with the affinity column material and place in one or more 50 ml centrifuge tubes at 4°C with gentle rotation for 30-120 min.

[0205] (3) Centrifuge at 3000 × g at 4°C for 1 min and discard the supernatant.

[0206] (4) Wash with 45 ml of pre-cooled PBS buffer.

[0207] (5) Add 10 ml of eluent (0.1 M glycine, pH 3.0) to the filler in sequence, 1 ml each time, and collect the antibody sample.

[0208] (6) SDS-PAGE detection of antibodies.

[0209] The results of expression and purification of 1A10, 1F3 and 3E12 cloned recombinant antibodies are as follows Figure 1 As shown in AC.

[0210] 3.4 Detection of positive recombinant antibody expression supernatant

[0211] The results of indirect ELISA detection of recombinant antibody expression supernatant are shown in Table 7.

[0212] Table 7 Indirect ELISA test results of recombinant antibody expression supernatant

[0213] Sample Information OD value A 1A10 1.724 B 1F3 1.529 C 2F3 0.455 D 3E12 1.589 E Blank control 0.074 F Blank control 0.076 G Blank control 0.095 H Positive Control 1.688

[0214] According to the test results, the antibody titer test value of 2F3 clone after recombinant expression was low, so it was discarded, and 1A10, 1F3 and 3E12 were selected to use the competition method to detect the specificity of the antibody and alliin small molecules. The results are shown in Table 8.

[0215] Table 8 Competitive ELISA test results of recombinant antibody expression supernatant

[0216]

[0217]

[0218] Note: The primary antibody in the negative control group was 200 μl PBS; the primary antibody in the positive control group was 50 μl of recombinant expression supernatant; the primary antibody in the competition group was 50 μl (concentration 20 μg / ml, i.e. 1 μg per well) alliin and 50 μl of recombinant expression supernatant.

[0219] Example 4

[0220] 4.1 Reagents and Materials

[0221] Alliin antibodies 1A10, 1F3 and 3E12 (experimental group), negative control (negative antibody), BSA-alliin, coating buffer (0.05 mol / L carbonate buffer, pH 9.6), washing buffer (PBS-T, PBS containing 0.05% Tween 20), blocking buffer (PBS containing 5% BSA), antibody diluent (PBS containing 1% BSA), enzyme conjugate (HRP-labeled goat anti-rabbit secondary antibody), color development reagent (TMB solution), stop solution (2M H2SO4), 96-well ELISA plate.

[0222] Experimental procedures

[0223] 4.2.1 Board coating

[0224] (1) Add 100 μL of coating buffer containing BSA-alliin small molecules to each ELISA plate well at a concentration of 2 μg / mL.

[0225] (2) Incubate at 4°C overnight.

[0226] (3) Pour off the coating solution and wash the plate three times with washing buffer, 300 μL each time.

[0227] 4.2.2 Board Closure

[0228] (1) Add 200 μL of blocking buffer to each well and incubate at room temperature for 1 hour.

[0229] (2) Pour off the blocking solution and wash the plate three times with washing buffer, 300 μL each time.

[0230] 4.2.3 Antibody incubation

[0231] (1) Different alliin antibodies (1 mg / ml) were diluted in antibody diluent according to different concentration gradients (1:500, 1:1000, 1:2000, 1:4000, 1:8000, 1:16000, 1:32000, 1:64000, 1:128000; i.e., 1:0.5K, 1:1K, 1:2K, 1:4K, 1:8K, 1:16K, 1:32K, 1:64K, 1:128K).

[0232] (2) Add 100 μL of diluted antibody solution to each well, including the experimental group and the negative control group.

[0233] (3) Incubate at 37°C for 1 hour.

[0234] (4) Pour off the antibody solution and wash the plate five times with 300 μL of washing buffer each time.

[0235] 4.2.4 Secondary Antibody Incubation

[0236] (1) Dilute HRP-labeled goat anti-rabbit secondary antibody (dilution ratio, 1:5000).

[0237] (2) Add 100 μL of diluted secondary antibody solution to each well.

[0238] (3) Incubate at 37°C for 1 hour.

[0239] (4) Pour off the secondary antibody solution and wash the plate five times with washing buffer, 300 μL each time.

[0240] 4.2.5 Color reaction

[0241] (1) Add 100 μL of color development reagent (TMB solution) to each well.

[0242] (2) Incubate at room temperature for 10-20 minutes, protected from light.

[0243] (3) Add 50 μL of stop solution (2M H2SO4) to each well to terminate the color development reaction.

[0244] 4.2.6 Results Reading

[0245] (1) Use an ELISA plate reader to read the absorbance value (OD450) at a wavelength of 450 nm.

[0246] (2) The potency of different antibodies (1A10, 1F3 and 3E12) against alliin small molecules was evaluated based on the absorbance values. The results are shown in Tables 9, 10 and 11, respectively.

[0247] Table 9

[0248]

[0249] Table 10

[0250]

[0251] Table 11

[0252]

[0253]

[0254] 4.3 Data Analysis

[0255] Experimental groups: OD450 values ​​of alliin antibodies at different dilution concentrations.

[0256] Negative control: OD450 value of control antibody.

[0257] Titer calculation: Compare the absorbance values ​​of the experimental group and the negative control group, draw the antibody titer curve, and determine the titer of the antibody to the alliin small molecule.

[0258] The results are as follows Figure 2-4 As shown. The EC affinity of the anti-alliin small molecule antibody 1A10 was obtained 50 :180.8ng / ml, anti-alliin small molecule antibody 1A10 antibody affinity EC 50 : 132.1ng / ml, and the affinity EC of anti-alliin small molecule antibody 1A10 50 :136.3ng / ml.

[0259] In summary, the complete antigen alliin-KLH prepared by the present invention has good immunogenicity and can stimulate New Zealand white rabbits to produce a strong immune response. After one basic immunization and three booster immunizations, the antiserum titer can reach 1:32k. The monoclonal antibodies 1A10, 1F3 and 3E12 against alliin finally obtained all have good affinity, and the antibody sequences are shown in Table B.

[0260] The sequence information of the present invention is shown in Table B.

[0261] Table B

[0262]

[0263]

[0264]

[0265]

[0266]

[0267]

[0268]

[0269] Note: The CDR sequences in the table are determined using the Kabat rule.

[0270] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. An anti-alliin antibody or an antigen-binding fragment thereof, the antibody or the antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, characterized in that: The complementarity determining region CDR (HCDR) of the heavy chain variable region and the complementarity determining region CDR (LCDR) of the light chain variable region are: The amino acid sequence of HCDR1 is shown in SEQ ID NO:30, The amino acid sequence of HCDR2 is shown in SEQ ID NO: 18, The amino acid sequence of HCDR3 is shown in SEQ ID NO:31, LCDR1 having an amino acid sequence as shown in SEQ ID NO:36, LCDR2 having an amino acid sequence as shown in SEQ ID NO: 11, and The amino acid sequence of LCDR3 is shown in SEQ ID NO:

37.

2. A recombinant protein, characterized in that The recombinant protein has: (i) the anti-alliin antibody or antigen-binding fragment thereof according to claim 1; and (ii) optionally a tag sequence to facilitate expression and / or purification.

3. A nucleotide molecule, characterized in that The nucleotide molecule encodes the anti-alliin antibody or antigen-binding fragment thereof according to claim 1.

4. A carrier, characterized in that The vector contains the nucleotide molecule according to claim 1.

5. A host cell, characterized in that The host cell contains the vector according to claim 4, or has the nucleotide molecule according to claim 3 integrated into its genome, or expresses the anti-alliin antibody or antigen-binding fragment thereof according to claim 1.

6. A method for detecting alliin in a sample, characterized in that: The method comprises the steps of: (1) contacting a sample with the anti-alliin antibody or antigen-binding fragment thereof as claimed in claim 1; (2) Detecting whether a hapten-antibody complex is formed, wherein the formation of the complex indicates the presence of alliin in the sample.

7. A method for preparing the anti-alliin antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The method comprises the following steps: (a) culturing the host cell according to claim 5 under expression conditions, thereby expressing the anti-alliin antibody or antigen-binding fragment thereof; (b) isolating and purifying the anti-alliin antibody or antigen-binding fragment thereof described in (a).

8. Use of the anti-alliin antibody or antigen-binding fragment thereof according to claim 1 and the recombinant protein according to claim 2, characterized in that: For preparing reagents, test plates or test kits; The reagent, detection plate or test kit is used for detecting whether a sample contains alliin, or for capturing alliin.

9. A detection board, characterized in that: The detection plate comprises a substrate (support sheet) and a test strip, wherein the test strip contains the anti-alliin antibody or antigen-binding fragment thereof as claimed in claim 1, or the recombinant protein as claimed in claim 2.

10. A kit, characterized in that: The kit comprises a container and the anti-alliin antibody or antigen-binding fragment thereof according to claim 1 located in the container, or the kit comprises the detection plate according to claim 9 and instructions for use.

Citation Information

Patent Citations

  • Alliin antigen and rabbit alliin antibody acquired through immune response of alliin antigen

    CN108948185A